肌萎缩侧索硬化症的多药疗法：多药治疗方法的依据。 - Suppr

Suppr

超能文献

Multi-drug therapy in amyotrophic lateral sclerosis: the case for a multi-drug approach.

作者信息

Rosenfeld Jeffrey

机构信息

Carolinas Neuromuscular/ALS Center, Charlotte, North Carolina, USA.

出版信息

Muscle Nerve. 2004 Nov;30(5):673-5. doi: 10.1002/mus.20186.

DOI:10.1002/mus.20186

PMID:15452840

Abstract

摘要

相似文献

Multi-drug therapy in amyotrophic lateral sclerosis: the case for a multi-drug approach.

Muscle Nerve. 2004 Nov;30(5):673-5. doi: 10.1002/mus.20186.

Multi-drug therapy in amyotrophic lateral sclerosis: combinations of multiple, untested drugs should not be used at this time.

Muscle Nerve. 2004 Nov;30(5):676-8. doi: 10.1002/mus.20187.

ALS combination treatment. Drug cocktails.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:115-7. doi: 10.1080/17434470410020067.

Clinical development of levetiracetam for amyotrophic lateral sclerosis.

Drug News Perspect. 2006 Nov;19(9):572-3.

What is next in ALS clinical trials?

Neurology. 2007 Aug 21;69(8):719-20. doi: 10.1212/01.wnl.0000271093.41793.ff.

Therapeutic trials in ALS.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Apr;4(1):6-7. doi: 10.1080/14660820310006643.

Regulatory issues in ALS clinical trials.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:36-41. doi: 10.1080/17434470410015964.

Re: What is next in ALS clinical trials?

Neurology. 2008 Apr 15;70(16):1366; author reply 1366-7. doi: 10.1212/01.wnl.0000316828.96520.19.

Designing clinical trials in amyotrophic lateral sclerosis.

Phys Med Rehabil Clin N Am. 2008 Aug;19(3):495-508, ix. doi: 10.1016/j.pmr.2008.02.002.

Baseline disease characteristics.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:64-7. doi: 10.1080/17434470410019924.

引用本文的文献

Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis.

Aging Dis. 2024 Feb 1;16(2):693-713. doi: 10.14336/AD.2024.0440.

Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke.

Neurotherapeutics. 2022 Mar;19(2):513-527. doi: 10.1007/s13311-022-01203-0. Epub 2022 Feb 28.

Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives.

Cells. 2021 Mar 5;10(3):565. doi: 10.3390/cells10030565.

Improving clinical trial outcomes in amyotrophic lateral sclerosis.

Nat Rev Neurol. 2021 Feb;17(2):104-118. doi: 10.1038/s41582-020-00434-z. Epub 2020 Dec 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Multi-drug therapy in amyotrophic lateral sclerosis: the case for a multi-drug approach.

Muscle Nerve. 2004 Nov;30(5):673-5. doi: 10.1002/mus.20186.

Multi-drug therapy in amyotrophic lateral sclerosis: combinations of multiple, untested drugs should not be used at this time.

Muscle Nerve. 2004 Nov;30(5):676-8. doi: 10.1002/mus.20187.

ALS combination treatment. Drug cocktails.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:115-7. doi: 10.1080/17434470410020067.

Clinical development of levetiracetam for amyotrophic lateral sclerosis.

Drug News Perspect. 2006 Nov;19(9):572-3.

What is next in ALS clinical trials?

Neurology. 2007 Aug 21;69(8):719-20. doi: 10.1212/01.wnl.0000271093.41793.ff.

Therapeutic trials in ALS.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Apr;4(1):6-7. doi: 10.1080/14660820310006643.

Regulatory issues in ALS clinical trials.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:36-41. doi: 10.1080/17434470410015964.

Re: What is next in ALS clinical trials?

Neurology. 2008 Apr 15;70(16):1366; author reply 1366-7. doi: 10.1212/01.wnl.0000316828.96520.19.

Designing clinical trials in amyotrophic lateral sclerosis.

Phys Med Rehabil Clin N Am. 2008 Aug;19(3):495-508, ix. doi: 10.1016/j.pmr.2008.02.002.

Baseline disease characteristics.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:64-7. doi: 10.1080/17434470410019924.

引用本文的文献

Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis.

Aging Dis. 2024 Feb 1;16(2):693-713. doi: 10.14336/AD.2024.0440.

Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke.

Neurotherapeutics. 2022 Mar;19(2):513-527. doi: 10.1007/s13311-022-01203-0. Epub 2022 Feb 28.

Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives.

Cells. 2021 Mar 5;10(3):565. doi: 10.3390/cells10030565.

Improving clinical trial outcomes in amyotrophic lateral sclerosis.

Nat Rev Neurol. 2021 Feb;17(2):104-118. doi: 10.1038/s41582-020-00434-z. Epub 2020 Dec 18.